LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) ("STAAR†), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICLâ"¢) for vision correction, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS†) has issued a new report and revised its recommendation with respect to STAAR's merger with Alcon. ISS is now recommending that all STAAR stockholders vote "FOR†STAAR's amended merger agree. ...